ID
44055
Description
Study documentation part: Pre-Treatment This is a phase III study of BMS-354825 in subjects with chronic myelogenous leukemia in accelerated phase, or in myeloid or lymphoid blast phase or with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia who are resistant or intolerant to imatinib mesylate (Gleevec).Trial Number: NCT00123487. Drug: dasatinib. Phase 3.
Keywords
Versions (4)
- 7/6/15 7/6/15 -
- 8/6/15 8/6/15 -
- 3/15/21 3/15/21 - Dr. rer. medic Philipp Neuhaus
- 9/20/21 9/20/21 -
Uploaded on
September 20, 2021
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0 Legacy
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Advanced Chronic Myelogenous Leukemia (CML) NCT00123487 – Pre-Treatment
Advanced Chronic Myelogenous Leukemia (CML) NCT00123487 – Pre-Treatment
Similar models
Advanced Chronic Myelogenous Leukemia (CML) NCT00123487 – Pre-Treatment
C0545082 (UMLS CUI-2)
No comments